HomeAI · summaries
Storia in 2 fonti
FDA extends review of Exelixis' colorectal cancer drug candidate
FDA extends review of Exelixis' zanzalintinib-Tecentriq combo in mCRC by three months to March 3 after new data submission.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
FDA extends review of Exelixis' colorectal cancer drug candidate
FDA extends review of Exelixis' zanzalintinib-Tecentriq combo in mCRC by three months to March 3 after new data submission.
- ·
benzinga.com
Exelixis Stock Slips as FDA Delays Cancer Drug Review - Exelixis (NASDAQ:EXEL)
FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.